| Budget Amount *help |
¥17,160,000 (Direct Cost: ¥13,200,000、Indirect Cost: ¥3,960,000)
Fiscal Year 2020: ¥5,460,000 (Direct Cost: ¥4,200,000、Indirect Cost: ¥1,260,000)
Fiscal Year 2019: ¥5,460,000 (Direct Cost: ¥4,200,000、Indirect Cost: ¥1,260,000)
Fiscal Year 2018: ¥6,240,000 (Direct Cost: ¥4,800,000、Indirect Cost: ¥1,440,000)
|
|---|
| Outline of Final Research Achievements |
With regard to the distribution of known driver mutations in papillary thyroid carcinoma in Japanese patients, BRAF V600E was found to be present in about 80%, NRAS Q61R in about 1%, and fusion gene in about 6% (driver mutation unknown: about 13%). In anaplastic carcinomas, BRAF V600E was found to be present in about 84% of cases.
In patients with 1- to 4-cm intrathyroidal papillary carcinoma (PTC), for which no clear indication for lobectomy (LT) or total thyroidectomy (TT) has been established, LT instead of TT can prevent overtreatment and reduce postoperative complications without compromising the outcome if the TERT promoter mutations are negative.
|
